Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cellular Origins of EGFR-driven Lung Cancer Cells Determines Sensitivity to Therapy

ABSTRACT: Cellular Origins of EGFR-driven Lung Cancer Cells Determines Sensitivity to Therapy

PROVIDER: PRJNA747984 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15188300.fastq.gz	Fastqsanger.gz
	SRR15188301.fastq.gz	Fastqsanger.gz
	SRR15188302.fastq.gz	Fastqsanger.gz
	SRR15188303.fastq.gz	Fastqsanger.gz
	SRR15188304.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 25

Similar Datasets

Cellular Origins of EGFR-driven Lung Cancer Cells Determines Sensitivity to Therapy

Project description:The purpose of this research is to study the cellular origins of EGFR-mutant lung cancers and their responses to therapies. We discovered that activation of EGFR T790M/L858R mutation in lung epithelial cells can drive lung cancers with alveolar or bronchiolar features, which can be originated from alveolar type 2 (AT2) cells or bronchioalveolar stem cells (BASCs), but not basal cells or club cells of the trachea. Crucially, the tumoroids with different cell-of-origins or epigenetic states had distinct drug vulnerabilities.

2021-09-18 | GSE180360 | GEO

Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy.

Project description:Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) is one of the major precision medicine treatment options for lung adenocarcinoma. Due to common development of drug resistance to first- and second-generation TKIs, third-generation inhibitors, including osimertinib and rociletinib, have been developed. A model of EGFR-driven lung cancer and a method to develop tumors of distinct epigenetic states through 3D organotypic cultures are described here. It is discovered that activation of the EGFR T790M/L858R mutation in lung epithelial cells can drive lung cancers with alveolar or bronchiolar features, which can originate from alveolar type 2 (AT2) cells or bronchioalveolar stem cells, but not basal cells or club cells of the trachea. It is also demonstrated that these clones are able to retain their epigenetic differences through passaging orthotopically in mice and crucially that they have distinct drug vulnerabilities. This work serves as a blueprint for exploring how epigenetics can be used to stratify patients for precision medicine decisions.

| S-EPMC8596110 | biostudies-literature

IRS1 phosphorylation determines a heritable probability of cancer cells to persist during EGFR inhibition therapy

Project description:Stochastic transition of cancer cells between drug-sensitive and drug-tolerant persister phenotypes has been proposed to play a key role in non-genetic resistance to therapy. Yet, we show here that cancer cells actually possess a highly stable inherited chance to persist (CTP) during therapy. This CTP is non-stochastic, determined pre-treatment, and has a unimodal distribution ranging from 0 to almost 100%. Importantly, CTP is drug-specific. We found that differential serine/threonine phosphorylation of the insulin receptor substrate 1 (IRS1) protein determines the CTP of lung and of head and neck cancer cells under EGFR inhibition, both in vitro and in vivo. Indeed, the first-in-class IRS1 inhibitor NT219 was highly synergistic with anti-EGFR therapy across multiple in vitro and in vivo models. Elucidation of drug-specific mechanisms that determine the degree and stability of cellular CTP may establish a framework for the elimination of cancer persisters, using novel rationally designed drug combinations.

2021-06-22 | PXD026834 | Pride

Selective polyprotein processing determines norovirus sensitivity to Trim7

Project description:Selective polyprotein processing determines norovirus sensitivity to Trim7

| PRJEB47213 | ENA

NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma